share_log

Redhill Biopharma | EFFECT: Others

Redhill Biopharma | EFFECT: Others

Redhill Biopharma | EFFECT:其他
美股SEC公告 ·  08/20 06:04
Moomoo AI 已提取核心信息
RedHill Biopharma Ltd., a biopharmaceutical company, has achieved a significant milestone with the United States Securities and Exchange Commission (SEC) declaring its Form F-3 effective as of August 19, 2024, at 4:30 P.M. This form is utilized by foreign private issuers to register various types of securities for public offering in the United States. The effectiveness of this form indicates that RedHill Biopharma has met all the necessary regulatory requirements to proceed with its public offering of securities.
RedHill Biopharma Ltd., a biopharmaceutical company, has achieved a significant milestone with the United States Securities and Exchange Commission (SEC) declaring its Form F-3 effective as of August 19, 2024, at 4:30 P.M. This form is utilized by foreign private issuers to register various types of securities for public offering in the United States. The effectiveness of this form indicates that RedHill Biopharma has met all the necessary regulatory requirements to proceed with its public offering of securities.
红山生物制药有限公司是一家生物制药公司,在2024年8月19日下午4:30,美国证券交易委员会(SEC)宣布其F-3表格有效。此表格用于外国私人发行人在美国注册各种证券进行公开发行。该表格的有效性表明红山生物制药已经满足了进行证券公开发行所需的所有监管要求。
红山生物制药有限公司是一家生物制药公司,在2024年8月19日下午4:30,美国证券交易委员会(SEC)宣布其F-3表格有效。此表格用于外国私人发行人在美国注册各种证券进行公开发行。该表格的有效性表明红山生物制药已经满足了进行证券公开发行所需的所有监管要求。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息